Harvard Bioscience, Inc. (HBIO)

NASDAQ: HBIO · IEX Real-Time Price · USD
2.96
+0.09 (3.14%)
Jan 27, 2023, 4:00 PM EST - Market closed
3.14%
Market Cap 123.31M
Revenue (ttm) 117.96M
Net Income (ttm) -6.89M
Shares Out 41.66M
EPS (ttm) -0.17
PE Ratio n/a
Forward PE 14.93
Dividend n/a
Ex-Dividend Date n/a
Volume 47,107
Open 2.89
Previous Close 2.87
Day's Range 2.83 - 3.00
52-Week Range 1.98 - 6.49
Beta 1.54
Analysts Buy
Price Target 3.98 (+34.46%)
Earnings Date Mar 14, 2023

About HBIO

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate rea... [Read more]

Sector Healthcare
CEO Mr. James W. Green
Employees 475
Stock Exchange NASDAQ
Ticker Symbol HBIO
Full Company Profile

Financial Performance

In 2021, HBIO's revenue was $118.90 million, an increase of 16.46% compared to the previous year's $102.10 million. Losses were -$288,000, -96.31% less than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for HBIO stock is "Buy." The 12-month stock price forecast is $3.98, which is an increase of 34.46% from the latest price.

Price Target
$3.98
(34.46% upside)
Analyst Consensus: Buy
Stock Forecasts

News

10 Stocks Under $10 for 2023

Welcome to January! The season of holiday gifts

3 weeks ago - InvestorPlace

Harvard Bioscience Announces CFO Transition

HOLLISTON, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the resignation of Michael Rossi, the Company's chief financial officer and ...

1 month ago - GlobeNewsWire

Harvard Bioscience (HBIO) Reports Q3 Loss, Misses Revenue Estimates

Harvard Bioscience (HBIO) delivered earnings and revenue surprises of -120% and 3.85%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Harvard Bioscience Announces Third Quarter 2022 Financial Results

“Fighting through challenging times while building the company and new technologies for the future.”  “Fighting through challenging times while building the company and new technologies for the future...

2 months ago - GlobeNewsWire

Harvard Bioscience Schedules Third Quarter 2022 Earnings Conference Call for November 8, 2022 at 4:30 PM ET

HOLLISTON, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for third quarter ended September 30, 2022 after the market closes on No...

3 months ago - GlobeNewsWire

Harvard Bioscience Announces Second Quarter 2022 Financial Results

HOLLISTON, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the second quarter ended June 30, 2022.

6 months ago - GlobeNewsWire

Harvard Bioscience Schedules Second Quarter 2022 Earnings Conference Call for August 4, 2022 at 8:00 AM ET

HOLLISTON, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for second quarter ended June 30, 2022 before the market opens on August...

6 months ago - GlobeNewsWire

Harvard Bioscience (HBIO) Loses 35.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Harvard Bioscience (HBIO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings ...

9 months ago - Zacks Investment Research

Harvard Bioscience (HBIO) Q1 Earnings and Revenues Lag Estimates

Harvard Bioscience (HBIO) delivered earnings and revenue surprises of -20% and 1.11%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

Harvard Bioscience Announces First Quarter 2022 Financial Results

HOLLISTON, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31, 2022.

9 months ago - GlobeNewsWire

Harvard Bioscience Introduces SmartStudy™: First of Kind, Next Generation Inhalation System Capability Improves Precision and Drives Growth

Company continues innovating preclinical tools used in new and ongoing small animal research and product development with SmartStudy™ Company continues innovating preclinical tools used in new and ong...

9 months ago - GlobeNewsWire

Harvard Bioscience Schedules First Quarter 2022 Earnings Conference Call for May 4, 2022 at 8:00 AM ET

HOLLISTON, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for first quarter ended March 31, 2022 before the market opens on May 4...

10 months ago - GlobeNewsWire

Harvard Bioscience Announces Fourth Quarter 2021 Financial Results

HOLLISTON, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the period ended December 31, 2021.

11 months ago - GlobeNewsWire

Harvard Bioscience Schedules Fourth Quarter 2021 Earnings Conference Call for March 8, 2022 at 8:00 AM ET

HOLLISTON, Mass., Feb. 21, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for fourth quarter ended December 31, 2021 before the market opens on Ma...

1 year ago - GlobeNewsWire

Harvard Bioscience (HBIO) Q3 Earnings Meet Estimates

Harvard Bioscience (HBIO) delivered earnings and revenue surprises of 0.00% and 5.56%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Harvard Bioscience Announces Third Quarter 2021 Financial Results

Strong double digit revenue growth, solid margin performance despite global supply chain disruptions

1 year ago - GlobeNewsWire

Harvard Bioscience (HBIO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Harvard Bioscience (HBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Harvard Bioscience Schedules Third Quarter 2021 Earnings Conference Call for November 3, 2021 at 8:00 AM ET

HOLLISTON, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for third quarter ended September 30, 2021, before the market opens on N...

1 year ago - GlobeNewsWire

Harvard Bioscience (HBIO) Tops Q2 Earnings and Revenue Estimates

Harvard Bioscience (HBIO) delivered earnings and revenue surprises of 20.00% and 6.56%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Harvard Bioscience Announces Second Quarter 2021 Financial Results

Strong double digit revenue growth, solid margin performance despite global supply chain disruptions

1 year ago - GlobeNewsWire

Harvard Bioscience (HBIO) Reports Next Week: What to Know Ahead of the Release

Harvard Bioscience (HBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Harvard Bioscience Schedules Second Quarter 2021 Earnings Conference Call for August 5, 2021 at 8:00 AM ET

HOLLISTON, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for second quarter ended June 30, 2021 before the market opens on August...

1 year ago - GlobeNewsWire

Are You Looking for a Top Momentum Pick? Why Harvard Bioscience (HBIO) is a Great Choice

Does Harvard Bioscience (HBIO) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 year ago - Zacks Investment Research

Harvard Bioscience (HBIO) Is a Great Choice for "Trend" Investors, Here's Why

Harvard Bioscience (HBIO) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed thr...

1 year ago - Zacks Investment Research

4 Breakout Stocks You Must Add Right Away to Your Portfolio

The logic behind this strategy for stock selection is to identify stocks that are trading within a narrow band.

Other symbols: DLTHGNKVEL
1 year ago - Zacks Investment Research